PEPTIDE COMPARISON

KPV vs LL-37

Two innate-immune research peptides with different mechanisms and similarly limited therapeutic evidence.

QUICK ANSWER

KPV vs LL-37: the main difference.

KPV and LL-37 are biologically different despite both appearing in inflammation and immune discussions. Neither endogenous or preclinical story establishes a safe, effective compounded therapy.

Decision field	KPV	LL-37
Human research	No established clinical efficacy program	No established marketed-product efficacy program
Primary biology	Melanocortin-derived anti-inflammatory signaling	Antimicrobial and inflammatory host defense
Preclinical research	Cell transport and mouse colitis	Broad antimicrobial and immune models
FDA status	Not approved; insufficient safety data	Not approved; insufficient safety data
Evidence confidence	Very low for clinical use	Very low for clinical use

SOURCES

KPV vs LL-37 sources.

Preclinical / 2008PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationPubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Review / 2025LL-37 in immunity and diseasePubMed Preclinical / 1998Antimicrobial activity of human cathelicidin LL-37PubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA

KPV vs LL-37: the main difference.

KPV vs LL-37 sources.

Questions related to KPV vs LL-37.

Compare the next decision.